Prelude Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Prelude Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-33,635	Closed	-$203K	–	2305
2019 Q4	$203K	Buy	+33,635	New	+$195K	0.01%	855
2017 Q3	–	Sell	-2,200	Closed	-$10K	–	2024
2017 Q2	$10K	Sell	2,200 -6,900	-76%	-$27.7K	﹤0.01%	1400
2017 Q1	$38K	Buy	+9,100	New	+$37.8K	﹤0.01%	1123
2016 Q4	–	Sell	-3,000	Closed	-$24K	–	1902
2016 Q3	$24K	Buy	+3,000	New	+$25.5K	﹤0.01%	1309
2013 Q4	–	Sell	-22,900	Closed	-$69K	–	2048
2013 Q3	$69K	Sell	22,900 -101,432	-82%	-$695K	0.01%	883
2013 Q2	$1.02M	Buy	+124,332	New	+$949K	0.22%	107

Prelude Capital Management's ACHN Position: Q1 2020 in Review

Prelude Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 33,635 shares — an estimated $203K sold.

Prelude Capital Management first reported a position in ACHN in Q2 2013 and held it in 6 quarters. The position peaked at $1.02M in Q2 2013. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

Prelude Capital Management reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Prelude Capital Management sold 33,635 Achillion Pharmaceuticals shares in Q1 2020, an estimated $203K.
Prelude Capital Management first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Prelude Capital Management's Achillion Pharmaceuticals position peaked at $1.02M in Q2 2013.
0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.